Allogeneic stem cell transplantation (alloSCT) is life-saving therapy for hematologic malignancies and? inherited disorders such as sickle cell anemia and thalassemia. T cells in alloSCT grafts play two pivotal? roles: 1) they reconstitute T cell immunity in adults who, due to thymic involution, do not develop significant? numbers of donor stem cell-derived T cells; and 2) they mediate an antineoplastic effect. Unfortunately,? donor T cells also cause Graft-vs.-Host Disease (GVHD), the attack of donor T cells against recipient? tissues. Therefore, all patients receive GVHD prophylaxis either via depletion of T cells from the allograft or? with agents that impair T cell function. Nevertheless, GVHD and the infectious complications of? immunosuppression are the major causes of morbidity in alloSCT. Professional antigen presenting cells? (APCs) initiate alloimmune T cell responses by priming rare alloreactive T cells. Several features? distinguish antigen presentation in transplantation. First, alloSCT recipients are chimeric for donor and host? APCs. Our work to date focused on characterizing the distinct roles for donor and host APCs in GVHD? pathogenesis. Second, DCs comprise a diverse set of cells with overlapping but distinct properties and the? roles for these DC subsets are not well defined in transplantation models. Third and perhaps most? important to the present application, the current paradigm for DCs in adaptive immunity, in which pathogenderived? ligands for pattern associated molecular pattern receptors (in particular Toll-like receptors),? stimulate immature DCs to mature and migrate to secondary lymph nodes, may not apply in alloSCT where? there are no specific infectious pathogens and signals that induce DC maturation are unknown. In this? proposal we plan to use a combination of reagents and gene deficient mice to define critical APC subsets in? GVHD, their pathways of maturation, and will test the hypothesis that their modulation can alter alloimmunity? for a therapeutic gain.?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI064343-01A1
Application #
7136041
Study Section
Allergy & Clinical Immunology-1 (AITC)
Project Start
2006-07-01
Project End
2011-07-31
Budget Start
2006-07-01
Budget End
2007-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$302,921
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Rothstein, David M; Camirand, Geoffrey (2015) New insights into the mechanisms of Treg function. Curr Opin Organ Transplant 20:376-84
Walch, Jeffrey M; Lakkis, Fadi G (2014) T-cell migration to vascularized organ allografts. Curr Opin Organ Transplant 19:28-32
Camirand, Geoffrey; Wang, Ying; Lu, Yuning et al. (2014) CD45 ligation expands Tregs by promoting interactions with DCs. J Clin Invest 124:4603-13
Oberbarnscheidt, Martin H; Zeng, Qiang; Li, Qi et al. (2014) Non-self recognition by monocytes initiates allograft rejection. J Clin Invest 124:3579-89
Walch, Jeffrey M; Zeng, Qiang; Li, Qi et al. (2013) Cognate antigen directs CD8+ T cell migration to vascularized transplants. J Clin Invest 123:2663-71
Reichenbach, D K; Li, Q; Hoffman, R A et al. (2013) Allograft outcomes in outbred mice. Am J Transplant 13:580-8
Isse, Kumiko; Lesniak, Andrew; Grama, Kedar et al. (2013) Preexisting epithelial diversity in normal human livers: a tissue-tethered cytometric analysis in portal/periportal epithelial cells. Hepatology 57:1632-43
Isse, K; Lesniak, A; Grama, K et al. (2012) Digital transplantation pathology: combining whole slide imaging, multiplex staining and automated image analysis. Am J Transplant 12:27-37
Zecher, Daniel; Li, Qi; Williams, Amanda L et al. (2012) Innate immunity alone is not sufficient for chronic rejection but predisposes healed allografts to T cell-mediated pathology. Transpl Immunol 26:113-8
Li, Hongmei; Demetris, Anthony J; McNiff, Jennifer et al. (2012) Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol 188:3804-11

Showing the most recent 10 out of 23 publications